DESTINY-BREAST 01, -02, -03: Age-specific pooled analysis
Trastuzumab deruxtecan (T-DXd) has been approved for the treatment of HER2-positive unresectable or metastatic breast cancer in patients who have received prior anti-HER2 therapy in the metastatic or (neo)adjuvant setting. This approval is based on the results of the randomized phase 3 DESTINY-Breast03 study.
It is known that older patients with HER2-positive metastatic breast cancer often experience poorer efficacy and safety outcomes regardless of the treatment received. However, the specific outcomes of older patients treated with T-DXd have not been extensively investigated.
During this year’s ASCO, Prof. Dr Krop presented age-specific efficacy and pooled safety analyses of T-DXd from the DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03 studies. These analyses compared the outcomes of patients below the age of 65 with those aged 65 and older.
To provide expert commentary on these results, Prof. Hans Wildiers from KUL, who has been recognized with the B.J. Kennedy Geriatric Oncology Award from the ASCO committee, is an excellent choice. His expertise in geriatric oncology makes him well-suited to provide insights into the implications of the age-specific efficacy and safety findings of T-DXd in older patients with HER2-positive metastatic breast cancer.
With the educational support of:
